China Resources Pharmaceutical Group Ltd

Chart & Performance

D1W1MN

No data to show

P/E

9.16

P/S

0.12

EPS

0.57

Div Yield, %

5.01%

Shrs. gr., 5y

-0.01%

Rev. gr., 5y

6.04%

Revenues

274.18b

+1.40%

Net income

3.57b

-7.49%

CFO

-100.00%

Dividend

Sep 10, 20240.0908 HKD/sh

Earnings

Aug 27, 2025

Profile

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The company operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. It offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it is involved in property holding activities. As of December 31, 2021, the company operated 801 retail pharmacies under the CR Care and Teck Soon Hong brands. It distributes its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.

URL

https://www.crpharm.com/

IPO date

Oct 28, 2016

Employees

71,000

Domiciled in

Incorporated in

Valuation

Order:

Title HKD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title HKD in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	274,182,490 1.40%	270,397,302 6.41%	254,106,366 7.31%
Cost of revenue	261,262,863	254,880,089	242,572,804
Unusual Expense (Income)
NOPBT	12,919,627	15,517,213	11,533,562
NOPBT Margin	4.71%	5.74%	4.54%
Operating Taxes	2,688,564	2,105,224	2,012,402
Tax Rate	20.81%	13.57%	17.45%
NOPAT	10,231,063	13,411,989	9,521,160
Net income	3,565,548 -7.49%	3,854,247 10.11%	3,500,270 13.62%
Dividends		(972,360)	(942,377)
Dividend yield		3.02%	2.37%
Proceeds from repurchase of equity		(516,835)	2,874,996
BB yield		1.60%	-7.24%
Debt
Debt current	48,280,233	46,223,589	56,013,044
Long-term debt	26,517,092	17,245,795	10,984,525
Deferred revenue		788,581	867,753
Other long-term liabilities	4,063,785	1,118,654	1,150,113
Net debt	50,783,241	31,940,222	21,328,042
Cash flow
Cash from operating activities		15,549,886	10,898,714
CAPEX		(3,461,644)	(3,356,325)
Cash from investing activities		(2,067,287)	(3,298,386)
Cash from financing activities		(4,472,401)	(9,001,601)
FCF	(47,726,214)	38,294,587	25,143,697
Balance
Cash	17,477,079	59,266,387	32,522,319
Long term investments	6,537,006	(27,737,225)	13,147,208
Excess cash	10,304,960	18,009,297	32,964,209
Stockholders' equity	104,371,771	102,324,859	90,182,333
Invested Capital	171,556,967	163,958,828	125,491,987
ROIC	6.10%	9.27%	7.11%
ROCE	7.10%	8.46%	7.20%
EV
Common stock shares outstanding	6,282,510	6,282,510	6,282,510
Price	5.70 11.11%	5.13 -18.83%	6.32 78.03%
Market cap	35,810,310 11.11%	32,229,279 -18.83%	39,705,466 78.03%
EV	139,630,057	115,892,590	101,656,422
EBITDA	12,919,627	19,013,830	14,685,712
EV/EBITDA	10.81	6.10	6.92
Interest		2,386,312	2,855,820
Interest/NOPBT		15.38%	24.76%